Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX) Following DMD data
Tweet Send to a Friend
Stifel analyst Annabel Samimy reiterated a Buy rating and $40.00 price target on Regenxbio Inc. (NASDAQ: RGNX) following new positive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
